X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (12) 12
index medicus (12) 12
female (9) 9
male (8) 8
aged (7) 7
multiple myeloma (7) 7
multiple myeloma - drug therapy (7) 7
multiple myeloma - pathology (7) 7
chemotherapy (6) 6
hematology (6) 6
middle aged (6) 6
treatment outcome (6) 6
analgesics (3) 3
antineoplastic agents - therapeutic use (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
antineoplastic combined chemotherapy protocols - therapeutic use (3) 3
boronic acids - administration & dosage (3) 3
boronic acids - adverse effects (3) 3
bortezomib (3) 3
cancer (3) 3
care and treatment (3) 3
imaging / radiology (3) 3
lenalidomide (3) 3
medicine & public health (3) 3
multiple myeloma - mortality (3) 3
nuclear medicine (3) 3
prognosis (3) 3
pyrazines - administration & dosage (3) 3
pyrazines - adverse effects (3) 3
thalidomide - administration & dosage (3) 3
thalidomide - adverse effects (3) 3
abridged index medicus (2) 2
adult (2) 2
article subject (2) 2
biotechnology & applied microbiology (2) 2
bone cements - therapeutic use (2) 2
combination (2) 2
corticosteroids (2) 2
dexamethasone (2) 2
dexamethasone - administration & dosage (2) 2
disease-free survival (2) 2
drug administration schedule (2) 2
efficacy (2) 2
elderly-patients (2) 2
fractures (2) 2
health aspects (2) 2
incidence (2) 2
initial treatment (2) 2
kaplan-meier estimate (2) 2
medical colleges (2) 2
medical research (2) 2
medicine (2) 2
medicine, experimental (2) 2
medicine, research & experimental (2) 2
melphalan - administration & dosage (2) 2
melphalan - adverse effects (2) 2
multiple myeloma - genetics (2) 2
multiple myeloma - metabolism (2) 2
multiple myeloma - therapy (2) 2
neoplasm staging (2) 2
oncology (2) 2
oral melphalan (2) 2
orthopedic surgery (2) 2
orthopedics (2) 2
pain (2) 2
pathology (2) 2
peripheral neuropathy (2) 2
phase-iii (2) 2
plus bortezomib (2) 2
prednisone - administration & dosage (2) 2
prednisone - adverse effects (2) 2
prednisone plus thalidomide (2) 2
proportional hazards models (2) 2
radiology, nuclear medicine & medical imaging (2) 2
randomized controlled trials as topic (2) 2
randomized controlled-trial (2) 2
retrospective studies (2) 2
review (2) 2
review article (2) 2
studies (2) 2
thalidomide (2) 2
usage (2) 2
vertebroplasty (2) 2
vertebroplasty - methods (2) 2
ablation (1) 1
acetylcysteine (1) 1
acetylcysteine - pharmacology (1) 1
acute leukemia (1) 1
age factors (1) 1
age factors; aged; antineoplastic combined chemotherapy protocols; cause of death; female; humans; male; multiple myeloma; neoplasm staging; prognosis; proportional hazards models; randomized controlled trials as topic; treatment outcome (1) 1
aged, 80 and over (1) 1
air-to-surface missiles (1) 1
alcoholism (1) 1
aldehydes (1) 1
allergic reaction (1) 1
allergy (1) 1
analgesia (1) 1
analysis (1) 1
animal cells (1) 1
anthracyclines (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Blood, ISSN 0006-4971, 12/2010, Volume 116, Issue 23, pp. 4745 - 4753
Journal Article
International Journal of Cancer, ISSN 0020-7136, 11/2012, Volume 131, Issue 9, pp. 2197 - 2203
Journal Article
Blood, ISSN 0006-4971, 01/2012, Volume 119, Issue 4, pp. 933 - 939
Journal Article
American Journal of Hematology, ISSN 0361-8609, 04/2014, Volume 89, Issue 4, pp. 355 - 362
Novel agents in combination with melphalan and prednisone (MP) significantly improved progression‐free survival (PFS) and overall survival (OS) in multiple... 
SURVIVAL | THERAPY | METAANALYSIS | EFFICACY | INITIAL TREATMENT | PLUS THALIDOMIDE | RANDOMIZED CONTROLLED-TRIAL | PHASE-3 | HEMATOLOGY | YOUNGER | TRANSPLANTATION | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Humans | Pyrazines - administration & dosage | Drug Evaluation | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Boronic Acids - adverse effects | Male | Case-Control Studies | Multiple Myeloma - drug therapy | Multiple Myeloma - therapy | Melphalan - adverse effects | Aged, 80 and over | Female | Retrospective Studies | Boronic Acids - administration & dosage | Thalidomide - adverse effects | Hematologic Diseases - chemically induced | Prednisone - administration & dosage | Bortezomib | Prednisone - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Thalidomide - administration & dosage | Randomized Controlled Trials as Topic | Disease-Free Survival | Melphalan - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pyrazines - adverse effects | Nervous System Diseases - chemically induced | Aged | Multiple Myeloma - genetics | Evidence, Expert | Medical research | Corticosteroids | Analysis | Multiple myeloma | Medicine, Experimental | Prednisone | Consulting services | Index Medicus | Clinical Medicine | Hematologi | Medical and Health Sciences | Hematology | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
European Journal of Haematology, ISSN 0902-4441, 09/2014, Volume 93, Issue 3, pp. 207 - 213
Objectives In vitro studies have shown synergistic anti‐myeloma effects of bortezomib combined with alkylating agents or anthracycline. We tested safety and... 
liposomal pegylated doxorubicin | cyclophosphamide | multiple myeloma | bortezomib | salvage therapy | Liposomal pegylated doxorubicin | Cyclophosphamide | Bortezomib | Salvage therapy | Multiple myeloma | REFRACTORY MULTIPLE-MYELOMA | RESPONSE CRITERIA | EFFICACY | SAFETY | PHASE-II | PLUS BORTEZOMIB | THALIDOMIDE | COMBINATION | ONCOLOGY | ORAL CYCLOPHOSPHAMIDE | HEMATOLOGY | Recurrence | Cyclophosphamide - administration & dosage | Multiple Myeloma - mortality | Humans | Middle Aged | Pyrazines - administration & dosage | Gastrointestinal Diseases - etiology | Salvage Therapy | Boronic Acids - adverse effects | Polyethylene Glycols - adverse effects | Dexamethasone - adverse effects | Male | Cyclophosphamide - adverse effects | Multiple Myeloma - drug therapy | Doxorubicin - analogs & derivatives | Female | Boronic Acids - administration & dosage | Doxorubicin - administration & dosage | Peripheral Nervous System Diseases - etiology | Dexamethasone - administration & dosage | Drug Administration Schedule | Thrombocytopenia - etiology | Antineoplastic Combined Chemotherapy Protocols | Treatment Outcome | Polyethylene Glycols - administration & dosage | Multiple Myeloma - pathology | Pyrazines - adverse effects | Survival Analysis | Aged | Doxorubicin - adverse effects | Care and treatment | Anthracyclines | Dexamethasone | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 5358 - 5358
Abstract Objectives: We recently identified the ratio between absolute neutrophils count and absolute lymphocyte count, NLR ≥2, as a predictor of progression... 
Journal Article
Journal Article
CardioVascular and Interventional Radiology, ISSN 0174-1551, 12/2010, Volume 33, Issue 6, pp. 1270 - 1277
Journal Article
Blood, ISSN 0006-4971, 11/2013, Volume 122, Issue 21, pp. 3138 - 3138
Abstract Introduction Multiple Myeloma (MM) is a plasma cell malignancy with a well documented immune dysfunction. However the role and function of neutrophils... 
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 5694 - 5694
Abstract Introduction Our previous work showed that in Multiple Myeloma (MM) the immune function is impaired, including immunosuppressive properties of... 
Journal Article
Blood, ISSN 0006-4971, 12/2014, Volume 124, Issue 21, pp. 198 - 198
Abstract Background: Autologous stem cell transplantation (ASCT) improves outcome in comparison with chemotherapy (CC) innewly diagnosed multiple myeloma... 
Journal Article